Updates in Chronic Lymphocytic Leukemia from the ICML 2023 Meeting and Beyond

home / news-network / updates-in-chronic-lymphocytic-leukemia-from-the-icml-2023-meeting-and-beyond

Brian T. Hill MD, PhD, and Paulo Ghia, MD engage with recent data focusing on BTKis in CLL presented at the ICML 2023 Annual Meeting as well as how that data may be applied to clinical practice.

Mechanism and Frontline Use of BTK Inhibitors in CLL

EP. 1: Mechanism and Frontline Use of BTK Inhibitors in CLL

July 14th 2023

Brian T. Hill, MD, Ph.D., and Paulo Gia, MD explain the mechanism of action of BTK inhibitors and the rationale behind their use in chronic lymphocytic leukemia (CLL).

Covalent BTK Inhibitors in Relapsed/Refractory CLL

EP. 2: Covalent BTK Inhibitors in Relapsed/Refractory CLL

July 14th 2023

Subject-matter experts review treatment options for patients with relapsed/refractory CLL.

Comparing BTK Inhibitors: Key Findings from Head-to-Head Trials

EP. 3: Comparing BTK Inhibitors: Key Findings from Head-to-Head Trials

July 21st 2023

An insightful analysis of head-to-head trials comparing BTK inhibitors (acalabrutinib vs ibrutinib and zanubrutinib vs ibrutinib) to guide treatment selection in CLL.

Clinical Considerations for BTK Inhibitor Treatment Selection

EP. 4: Clinical Considerations for BTK Inhibitor Treatment Selection

July 21st 2023

Dr. Hill and Dr. Gia share how varying risk profiles of different BTK inhibitors may impact patient outcomes, along with relevant real-world data.

Molecular Mechanisms of Resistance to Acalabrutinib in CLL

EP. 5: Molecular Mechanisms of Resistance to Acalabrutinib in CLL

July 25th 2023

Exploring molecular mechanisms of resistance to BTK inhibitors as well as emergent data concerning how this resistance might be overcome.

Treatment Options for Patients with CLL Progressing on Covalent BTK Inhibitors

EP. 6: Treatment Options for Patients with CLL Progressing on Covalent BTK Inhibitors

July 25th 2023

Dr. Hill and Dr. Gia discuss treatment options for patients who progress on covalent and noncovalent BTK inhibitors.